Vortioxetine - pharmacological properties and use in mood disorders. The current state of knowledge.

IF 0.9 4区 医学 Q4 PSYCHIATRY Psychiatria polska Pub Date : 2023-12-31 DOI:10.12740/PP/OnlineFirst/151570
Anna Julia Krupa, Krzysztof Wojtasik-Bakalarz, Marcin Siwek
{"title":"Vortioxetine - pharmacological properties and use in mood disorders. The current state of knowledge.","authors":"Anna Julia Krupa, Krzysztof Wojtasik-Bakalarz, Marcin Siwek","doi":"10.12740/PP/OnlineFirst/151570","DOIUrl":null,"url":null,"abstract":"<p><p>Vortioxetine is an antidepressant with a unique profile of receptor activity. The pharmacodynamic spectrum of vortioxetine activity is linked to the modulation of not only serotoninergic but also noradrenergic and dopaminergic transmission. At the same time, its pharmacokinetic properties determine good tolerance and safety, which are also observed in elderly patients and those burdened with somatic comorbidity. This work aims to sum up the knowledge coming from the most recent studies assessing the efficacy of vortioxetine. The efficacy of vortioxetine in the treatment of depression was confirmed in a large number of open studies, randomized controlled studies with placebo control, and meta-analyses thereof. What is more, the latest research shows that this drug allows depressed patients to achieve not only symptomatic remission but also an improvement of anhedonia and recovery in cognitive and occupational function. Furthermore, there are studies showing that vortioxetine is efficacious in the treatment of elderly patients, as well as subjects who have experienced trauma or suffer from bipolar depression. Vortioxetine is characterized by a good tolerance profile and safety; rarely does it cause severe adverse effects.</p>","PeriodicalId":20863,"journal":{"name":"Psychiatria polska","volume":" ","pages":"1109-1126"},"PeriodicalIF":0.9000,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatria polska","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12740/PP/OnlineFirst/151570","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Vortioxetine is an antidepressant with a unique profile of receptor activity. The pharmacodynamic spectrum of vortioxetine activity is linked to the modulation of not only serotoninergic but also noradrenergic and dopaminergic transmission. At the same time, its pharmacokinetic properties determine good tolerance and safety, which are also observed in elderly patients and those burdened with somatic comorbidity. This work aims to sum up the knowledge coming from the most recent studies assessing the efficacy of vortioxetine. The efficacy of vortioxetine in the treatment of depression was confirmed in a large number of open studies, randomized controlled studies with placebo control, and meta-analyses thereof. What is more, the latest research shows that this drug allows depressed patients to achieve not only symptomatic remission but also an improvement of anhedonia and recovery in cognitive and occupational function. Furthermore, there are studies showing that vortioxetine is efficacious in the treatment of elderly patients, as well as subjects who have experienced trauma or suffer from bipolar depression. Vortioxetine is characterized by a good tolerance profile and safety; rarely does it cause severe adverse effects.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
伏替西汀--药理特性及在情绪障碍中的应用。知识现状。
伏替西汀是一种具有独特受体活性的抗抑郁药。伏替西汀的药效学活性不仅与调节血清素能有关,还与调节去甲肾上腺素能和多巴胺能的传递有关。同时,它的药代动力学特性决定了其良好的耐受性和安全性,这一点在老年患者和有躯体合并症的患者身上也得到了体现。本研究旨在总结最近评估伏替西汀疗效的研究成果。大量开放性研究、安慰剂对照的随机对照研究及其荟萃分析均证实了伏替西汀治疗抑郁症的疗效。此外,最新的研究表明,这种药物不仅能使抑郁症患者的症状得到缓解,还能改善失乐症,恢复认知和职业功能。此外,还有研究表明,伏替西汀对老年患者以及经历过创伤或患有躁郁症的受试者也有疗效。伏替西汀具有良好的耐受性和安全性,很少引起严重的不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Psychiatria polska
Psychiatria polska 医学-精神病学
CiteScore
2.30
自引率
23.50%
发文量
92
审稿时长
6-12 weeks
期刊介绍: Information not localized
期刊最新文献
Study directions and development of cognitive theory of depression. Prevalence and determinants of psychotropic medication use in Poland. Efficacy and safety of aripiprazole in the treatment of delirium. An outline of savant syndrome. Use of the opioid receptor antagonist - naltrexone in the treatment of non-suicidal self-injury.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1